3-iodo-2-hydroxy-6-methoxy-n-((1-ethyl-2-pyrrolidinyl)methyl)benzamide has been researched along with Hallucinations in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dresel, S; Horak, M; Rüther, T; Soyka, M; Tatsch, K | 1 |
| Ballinger, JR; Fornazzari, L; Ichise, M; Kirsh, JC; Toyama, H | 1 |
2 other study(ies) available for 3-iodo-2-hydroxy-6-methoxy-n-((1-ethyl-2-pyrrolidinyl)methyl)benzamide and Hallucinations
| Article | Year |
|---|---|
PET and SPECT findings in alcohol hallucinosis: case report and super-brief review of the pathophysiology of this syndrome.
Topics: Alcoholism; Benzamides; Brain; Fluorodeoxyglucose F18; Hallucinations; Humans; Iodine Radioisotopes; Male; Middle Aged; Pyrrolidines; Radiopharmaceuticals; Serotonin; Syndrome; Tomography, Emission-Computed; Tomography, Emission-Computed, Single-Photon | 2000 |
Dopamine D2 receptor SPECT imaging: basic in vivo characteristics and clinical applications of 123I-IBZM in humans.
Topics: Adult; Aged; Alcoholism; Benzamides; Female; Hallucinations; Humans; Huntington Disease; Male; Middle Aged; Pyrrolidines; Receptors, Dopamine D2; Tomography, Emission-Computed, Single-Photon | 1993 |